South Rampart Pharma

Executive Summary

South Rampart Pharma is a clinical-stage biopharmaceutical company developing novel non-opioid, non-NSAID small molecule analgesics. Its lead candidate, SRP-001, targets an innovative mechanism to provide pain relief while avoiding the hepatotoxicity associated with acetaminophen and the gastrointestinal/renal risks of NSAIDs, as well as the addiction potential of opioids. Founded in 2018 and based in New Orleans, the company recently advanced SRP-001 into Phase 2 clinical trials. The drug's differentiated safety profile addresses a substantial unmet need in pain management, where current options are limited by organ toxicity and abuse liability. With a focused pipeline and a clear value proposition, South Rampart represents a promising opportunity in the analgesic space, albeit at an early clinical stage.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 top-line data readout for SRP-00135% success
• Q2 2027Potential partnering or licensing deal for SRP-00125% success
• Q1 2027Initiation of Phase 2b/3 enabling studies40% success